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Summary
Uromodulin (UMOD) is a glycoprotein excreted by the thick ascending limb of the Henle’s 
loop and distal convoluted tubule cells, playing various, yet still unclear roles. An abnor-
mal urinary UMOD excretion is observed in many pathophysiological conditions. The aim 
of our study was to assess urine UMOD excretion in experimental partial bladder outlet 
obstruction (PBOO), reflecting BPH in humans, and in cyclophosphamide-induced haem-
orrhagic cystitis (CP-HC). 
PBOO and CP-HC rats and two appropriate control groups were studied. The PBOO model 
was surgically induced by partial proximal urethral obstruction and CP-HC by four i.p. 
cyclophosphamide administrations (every two days). 24-hour urine collections were per-
formed in both PBOO (on 3rd, 7th, 12th and 15th day after surgery) and CP-HC rats (on 1st, 
3rd, 5th and 7th day). UMOD was determined with the ELISA method. Both 24-hour urinary 
UMOD excretion and urinary UMOD concentrations were determined.
In the overall assessment, PBOO rats were characterized by decreased mean urinary UMOD 
concentration. However, as the urine volume, except for transient  drop on 3rd day follow-
ing PBOO operation,  was steadily increasing, the daily urinary uromodulin excretion did 
not differ from the control one. 
Contrary to PBOO, CP-HC rats demonstrated mean urinary concentration similar to that 
of the control rats, while their 24hr UMOD excretion in urine was almost doubled due to 
urine volume increase (from 1.6 up to almost 3 fold). The highest UMOD urinary output 
was observed after the 3rd and 4th doses of cyclophosphamide. 
A reduced urinary UMOD excretion in early PBOO phase may be considered as a marker of 
distal tubular cells damage due to incomplete bladder emptying and increased pressure 
retrograding to distal tubules. This effect disappears with structural, adaptive histological 
changes of the bladder wall leading to an improved voiding. In CP-HC animals, the elevated 
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IntroductIon
Normal voiding is a complex phenomenon which may 
be disturbed and manifested as urgency, with (“wet” 
form) or without (”dry”) urge incontinence, usually in 
the presence of frequency and nocturia. That syndrome 
is referred to as “overactive bladder” (OAB) and is ma-
inly used for description of those disturbances in which 
no precise, local or systemic etiological cause, could be 
identified. The pathophysiology of this “primary” OAB 
remains not completely understood, however some hy-
potheses (with the most accepted neurologic and my-
ogenic ones) are proposed. They are given in details in 
some reviews [2,6,14], also of our authorship [9]. 
Despite the common accepted OAB definition given abo-
ve, this term is also currently applied to the description 
of secondary bladder overactivity symptoms, observed 
in various organic dysfunctions. One of them is benign 
prostatic hyperplasia (BPH) in men - an abnormality 
that leads to detrusor overactivity due to the bladder 
wall restructure with hyper-proliferated IC cells and 
fibroblasts, increased production of nerve (NGF), vascu-
lar (VEGF) and fibroblastic (FGF) growth factors, over-
production of reactive oxygen species due to hypoxia, 
neuronal enlargement and supersensitivity to locally 
released acetylcholine [2,3]. The increased infravesi-
cal pressure due to incomplete bladder emptying and 
urine retention is moved backwards, possibly as far as 
renal distal tubes. 
Secondary OAB symptoms due to acute bladder inflam-
mation are also observed in patients treated with alky-
lating, cytotoxic oxazaphosphorine agents (e.g. cyclo-
phosphamide - CP), used in pharmacotherapy of some 
neoplastic disorders. CP urotoxicity is related to its me-
tabolic pathway into aldophosphamide form, and sub-
sequent release of acrolein that exacerbates both cel-
lular and chemical inflammatory changes [34]. We have 
provided a detailed pathophysiological description of 
CP-induced bladder inflammation in one of our previo-
usly published papers [10]. Summing up, in both ob-
struction-associated and chemical bladder injury (with 
subsequent damage of distal tubules), some secondary 
OAB symptoms are observed.
The partially bladder outlet obstruction (PBOO) in rat 
is an experimental model reflecting pathological condi-
tions observed in human BPH [25]. Haemorrhagic cysti-
tis with kidney damage may be also produced in rats by 
cyclophosphamide administration (CP-HC model) [5,8]. 
Thus, using those two experimental models, a secon-
dary, overactivity-associated morphological bladder 
damage can be observed. According to our knowledge, 
currently there is no biochemical marker of bladder 
overactivity in those two conditions. Because kidneys 
are also involved in the pathophysiological process of 
both PBOO and CP-HC, it is hypothetically possible to 
use as a marker any constituent, that is excreted in 
an excessive amount by impaired kidneys. One of the 
potential candidates is a protein excreted into urine - 
uromodulin (UMOD).
Little is known about UMOD excretion secondary to either 
cytotoxic cyclophosphamide urinary tract damage or uri-
ne outflow obstruction, in the course of BPH. Thus, the 
aim of our study was to assess urine uromodulin excretion 
in two experimental OAB models: partial bladder outlet 
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urinary UMOD level may be associated with complex inflammatory response due to the cy-
totoxic CP action. UMOD assessment in this model may reflect renal and urological toxicity 
as UMOD excretion rises with the cumulative cyclophosphamide dose.
uromodulin • overactive bladder (OAB) • bladder outlet obstruction • haemorrhagic cystitis 
 • cyclophosphamide 
Keywords:
Abbrevations: AHL - ascending limb of the Henle’s loop, BPH – benign prostatic hyperplasia, BWW – bladder 
wet weight, CP – cyclophosphamide, CP-HC – cyclophosphamide-induced haemorrhagic cystitis, 
DCT – the distal convoluted tubule, LUT – lower urinary tract, OAB – overactive bladder, PBOO – 
partial bladder outlet obstruction, UMOD – uromodulin.
1186
Postepy Hig Med Dosw (online), 2014; tom 68: 1184-1192
obstruction (reflecting BPH in humans) and in cyclopho-
sphamide-induced haemorrhagic cystitis.
MaterIal and Methods
ANIMALS: Forty 6-weeks-old Wistar rats obtained from 
the central animal house of the Pharmaceutical Faculty of 
the Jagiellonian University Collegium Medicum in Krakow 
were used for experiments. For acclimatisation to the new 
living conditions, in the first week animals were placed in 
five collective cages with unlimited access to a standard 
laboratory feed (Labofeed, Kcynia) and water. Constant 
temperature of 22°C was maintained in the room. At the 
beginning of the experiment rats were randomised into 
study groups, 10 animals each. During the experiment, 
animals in the particular group lived together in the same 
cage and had unlimited access to water and feed.
STUDIED GROUPS: We performed our study using 
two experimental secondary OAB models – obstruc-
tive, with partial bladder outlet obstruction (PBOO) 
and chemical, cyclophosphamide-induced (CP-HC), 
with two appropriate control groups (control (1) and 
(2), respectively). Animals in the control (1) group un-
derwent a sham operation (PBOO surgery but without 
proximal partial urethral ligation). Control (2) animals 
were sham treated - they received normal (0.9%) saline 
solution instead of CP, in volume corresponding to the 
volume of CP applied in CP-HC group.
In the PBOO group, one rat did not survive the anaes-
thetic agent dose,  and another one died in an early post-
surgical period. The third PBOO subject was excluded 
as PBOO criteria failure because of a loosened urethral 
ligation revealed in final laparotomy. Finally, there were 
7 animals in the PBOO group. In the appropriate control 
(1) group, two animals also did not survive the sham pro-
cedure, thus 8 control individuals completed the study.
Out of 10 rats included into the CP-HC group, only 6 com-
pleted the study and 4 died before reception of the last 
CP dose. A cumulative nephro- and urotoxicity of the ap-
plied CP dose was a possible reason of that high mortality 
rate in that group. The remaining animals were gener-
ally in poor condition, deteriorating with each CP dose. 
In control (2) group, all 10 animals completed the study 
and exhibited the best condition of all studied groups.
THE PBOO SURGERY: Ten animals had the proximal 
section of the urethra partially surgically ligated, in or-
der to create the bladder outlet obstruction. According 
to the literature, a condition clinically corresponding to 
BPH with bladder overactivity develops within two weeks 
post-surgically [7,25]. The procedure was performed un-
der pentobarbital anaesthesia (Morbital, Puławy, 45mg/
kg b.w. administered i.p.). Following the anaesthesia, a 
medial incision was made in the projection over the blad-
der. The exposed bladder was carefully separated from the 
surrounding fatty tissue, and the urethra was catheter-
ised (polyethylene catheter, diameter 0.58mm), ligating 
the proximal section of the urethra around the catheter. 
After the catheter was removed, the abdominal integu-
ment and skin were sutured in layers with standard sur-
gical sutures (Medilen 4/0 USP; cutting needle DS2, 3/8). 
The surgical wound was sprayed with Neomycin and the 
surrounding skin was sprayed with Oxycort to minimise 
the risk of post-surgical infection. Two first days after 
the surgery were treated as a convalescence period. Data 
collection was started on the 3rd day.
CP-INDUCED HAEMORRHAGIC CYSTITIS: In 
another ten animals an experimental model of haemor-
rhagic cystitis with bladder overactivity was created by 
four (every two days – on days one, three, five and seven) 
intraperitoneal administrations of cyclophosphamide - 
CP (Sigma Aldrich) – at the dose of 75mg/kg b.w. The CP 
solution was prepared each time ex tempore before admin-
istration. According to the literature that dosage scheme 
leads to haemorrhagic cystitis following the fourth dose 
[5,8]. Control (2) animals received injections of normal sa-
line. Data acquisition was started with administration of 
the 1st CP dose.
BODY WEIGHT MEASUREMENT AND DAILY 
URINE COLLECTION: Body weight was measured in 
conscious rats using standard laboratory electronic scale, 
and the daily urine output was taken using standard meta-
bolic cages. During the 24-hour urine collection, each of 
the study individuals was placed in a separate cage with 
unlimited access to water and feed. In PBOO animals, body 
weight and daily urine output were measured on the 3rd, 
7th, 12th and 15th day after the surgery. Control (1) rats were 
studied once at the beginning of the experiment on the 3rd 
day. The measurement was accepted as a reference value. 
In CP-HC individuals, body weight and daily urine output 
was measured on the 1st, 3rd, 5th and 7th day, consistently 
with the administration of CP doses. Body weight was taken 
before each CP administration and then the studied rats 
were placed in metabolic cages. Measurements of control 
(2) rats were taken on the day 1 only, and results were ac-
cepted as a reference point for CP-HC animals.
We did not study control rats in parallel to PBOO/CP-
HC ones because we had made an assumption that in 
normal animals urine production and uromodulin ex-
cretion are stable over the time (15 or 7 days for PBOO 
and CP-HC, respectively). Therefore, we had decided to 
perform a single measurement in the control (1) group 
on the 3rd day after the sham surgery (those rats ex-
hibited no signs of postoperative abnormalities at that 
time) and in the control (2) group on the 1st day of the 
experiment (those animals were totally intact except 
a single saline administration).
UROMODULIN ASSESSEMENT: Rat uromodulin 
level was measured in urine samples using a commercially 
available ELISA kit (WUHAN EIAAB SCIENCE CO.,LTD), 
strictly according to the manufacturer’s instructions. 
Uromodulin concentrations (in [ng/ml]) in appropriate 
groups and time points (along with the total estimation) 
1187
Dobrek Ł. et al. – Urine Uromodulin Estimation In Partial Bladder Outlet Obstruction...
were obtained. We calculated also the amount of daily 
excreted  uromodulin in reference to the 24-hour urine 
measurement in all studied cases.
BLADDERS WET WEIGHT MEASUREMENT AND 
HISTOPATHOLOGICAL ASSESSEMENT: Following 
the last body weight and daily urine output measurement 
animals were sacrificed with a lethal dose of pentobarbital 
(Morbital, Puławy, Poland; 100 mg/kg b.w.). The bladder was 
collected from every study animal, following a previous sep-
aration from the surrounding fatty tissue and voiding. Ac-
cording to the literature data, the bladder wet weight (BWW) 
may be treated as an indirect evidence of the bladder recon-
struction induced by inflammation (in the CP-HC model) or 
by outlet obstruction (in the PBOO model), associated with 
its overactivity [23,32,42]. Directly after collection, bladders 
were weighed on an analytical scale and then placed in 4% 
formalin solution with PBS for histopathological evaluation.
STATISTICAL ANALYSIS: The results were presented 
as means ± SD. Paired results were analysed for groups: 
PBOO-control (1) and CP-HC-control (2) using the Fischer 
Snedecor test. In uromodulin estimation, we juxtaposed 
total results as well as those assessed on a particular day 
of the experiment (in PBOO participants) or estimated 
after a respective CP dose (in CP-HC animals).
results
Results of body weight and daily urine volume 
measurements
In PBOO animals, we observed a progressive body we-
ight increase during the experiment. On the contrary, 
CP-HC rats exhibited a progressing body weight loss 
with administration of subsequent CP doses. Observed 
changes are given in Tables 1 and 2.
Along with the body weight increase, a slight progressi-
ve rise in 24-hour urine output was also noted in PBOO. 
However, on the 3rd day after PBOO induction, the 
rats excreted even less urine than the control. It may 
be a consequence of the surgery and reduced bladder 
contraction, inappropriate to existing partial proximal 
urethral obstruction. From the day 7 onwards a trend 
of increased urine volumes was observed in that group 
as compared to the control counterpart. CP-HC rats, on 
all studied days, were characterised by higher diurnal 
urine volumes excretion compared to the control ones. 
The detailed results of observed 24-hour urine output 
in all studied groups are given in Tables 1 and 2.
Table 1. Partial bladder outlet obstruction (PBOO) rats characterization 
Control
(1)
PBOO
D3 
3rd day
D7 
7th day
D12 
12th day
D15
 15th day
body weight 
[g]
177.13±8.41 174.60±6.80 190.60±8.17 * 198.60±6.88 *** 203.20±8.59 ***
24-hour urine volume 
[ml]
3.59±1.50 2.72±0.72 4.37±2.29 5.90±2.04 * 6.90±1.02 ***
bladder wet weight 
[g]
0.14±0.06 n/e n/e n/e 0.26±0.16
Statistical significance: n/e – not estimated, * - p<0.05; ** - p<0.01; *** - p<0.001
Table 2. Cyclophosphamide-induced haemorrhagic cystitis (CP-HC) rats characterization
Control
(2)
CP-HC
D1
(1st dose)
D2
(2nd dose)
D3
(3rd dose)
D4
(4th dose)
body weight 
[g]
185.88±9.96 188.00±11.83 184.50±9.09 183.67±9.37 181.67±10.61
24-hour urine volume 
[ml]
5.90±1.52 9.50±4.37 13.42±10.41 17.42±9.36 * 14.83±6.43 **
bladder wet weight 
[g]
0.17±0.06 n/e n/e n/e 0.13±0.03
Statistical significance: n/e – not estimated, * - p<0.05; ** - p<0.01; *** - p<0.001
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EVALUATION OF BLADDER WET WEIGHT: Ac-
cording to the literature [23,32,42], the BWW measurement 
was intended as an indirect evidence of bladder dysfunc-
tion in studied models. In the PBOO group (group 1), on 
the day 15 of the experiment, the bladder wet weight was 
almost double compared to the control. It might be due to 
the suspected bladder wall reconstruction associated with 
the bladder attempts to overcome the partial urethral ob-
struction. On the other hand, CP-HC, CP-HC animals had 
lower BWW compared to the control. However, the above 
mentioned differences in both PBOO and CP-HC groups were 
not statistically significant. The detailed results of measured 
BWW are given in Tables 1 and 2.
HISTOLOGICAL ANALYSIS OF COLLECTED 
BLADDERS. According to the pathomorphological 
evaluation, bladders collected from PBOO animals dem-
onstrated signs of oedema and congestion of the blad-
der wall, with a minimal hyperplasia of the muscular 
layer. In the CP-HC model, a clear oedema and signs of 
congestion (mostly of the cystic mucosa) were found, 
along with signs of focal proliferation of fibroblasts in 
the mucosal lamina propria, mostly around some fine, 
submucosal blood extravasations. Fine lymphocytic in-
flammatory infiltrations were visible in the vicinity of 
vessels of the mucosal lamina propria. Epithelium of 
the bladder lining demonstrated focal ulceration with 
signs of clear proliferation of cells and of anisonuleosis 
focalis et papillosis. 
Uromodulin analysis – urine uromodulin 
concentration 
THE PBOO MODEL: The total urine UMOD concen-
trations were significantly (p<0.01) lower in PBOO ani-
mals (4.497 ± 0.646 ng/ml, comparing to control (1) ones 
(5.784 ± 0.775 ng/ml). The differences were also revealed 
on individual days, and they were strongly statistically 
significant. A marked decreasing trend of that parameter 
was observed on subsequent days.
THE CP-HC MODEL: Contrary to PBOO findings, an 
increasing trend of urine UMOD concentrations was ob-
served with subsequent CP doses. However, both the total 
result (5.410 ± 1.105 ng/ml) and values of UMOD concen-
trations calculated for three successive doses (1-3) were 
not statistically significant compared to the control (5.238 
± 0.960 ng/ml). Only the concentration value calculated 
following the 4th CP dose was significantly (p<0.05) higher 
in CP-HC than in the control.
Details of the results described above are given in Figures 
1 and 2 which present UMOD concentration changes dur-
ing  the course of experiment.
Uromodulin analysis – 24-hour urine uromodulin 
excretion 
THE PBOO MODEL: Total excreted UMOD amount 
was almost identical in PBOO (22.791 ± 8.827 ng/day) and 
control (1) individuals (22.819 ± 8.209 ng/day). However, 
considering 24-hour excreted UMOD changes, an increas-
ing trend was revealed in PBOO rats, similar to the urine 
volume changes observed in that group. On the 3rd day a 
statistically significant reduction of the UMOD amount 
was observed, and on the 15th day the UMOD excretion 
was the highest, compared to the control.
THE CP-HC MODEL: Contrary to the findings 
in PBOO animals, the total 24-hour UMOD excretion 
was almost doubled in CP-HC rats (59.192 ± 26.710 ng/
day) comparing to control (2) ones (34.159 ± 6.153 ng/
day) and that difference was statistically significant 
(p<0,0001). The group demonstrated also an increas-
ing trend of 24-hour excreted UMOD changes, except 
for the value calculated after the second CP dose. The 
highest excreted UMOD values were noted after the 3rd 
and the 4th CP  dose and they were statistically signifi-
cant comparing to control.
Details of the results described above are given in Figures 
3  and 4. They illustrate changes of the UMOD excretion 
in time, also showing the hypothetical course of UMOD 
changes also on remaining days of the experiment, that 
we didn’t make any calculations for.
Fig. 2. Uromodulin urine concentration changes in CP-HC rats
Fig. 1. Uromodulin urine concentration changes in PBOO rats
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dIscussIon
The main findings of our study are:
1. In the total assessment, PBOO rats were characterized by 
unchanged daily urinary uromodulin excretion compared 
to the control. However, due to the increased voiding, the 
UMOD mean urinary concentration in those animals was 
decreased. Contrary to PBOO findings, CP-HC rats demon-
strated almost doubled total 24hr UMOD excretion with 
mean urinary concentration being unchanged compared 
to the control. 
2. Considering time-dependent changes of the urinary 
UMOD we have found, that PBOO rats exhibited an incre-
asing trend, with significantly decreased (on the 3 day 
after the BOO surgery) and increased (on the day 15, re-
spectively) urinary UMOD amount. UMOD concentrations 
were significantly lower on all days of the experiment 
compared to the control. CP-HC individuals also demon-
strated a generally increased trend in 24-hour UMOD uri-
nary excretion. However, the more cumulative exposure to 
CP was applied (after 3rd and 4th doses), the higher UMOD 
amount excreted with urine was observed. The urinary 
UMOD concentrations were similar to those observed in 
the control, except for the calculated concentration fol-
lowing the reception of the fourth CP dose, that showed a 
significantly higher value compared to the control. 
Uromodulin is the most abundant urinary protein in 
healthy individuals, excreted into urine by the thick 
ascending limb of the Henle’s loop (AHL) and the distal 
convoluted tubule (DCT), constituting physiological hy-
aline casts [40]. UMOD is also known as the Tamm-Hors-
fall protein (THP), because it was discovered by Igor 
Tamm and Frank Horsfall in 1950 during a precipitation 
procedure of urine collected from healthy individuals, 
aimed at isolation of an inhibitor of hemagglutination 
of viruses (the authors attempted to obtain a compound 
that would prevent viruses from binding to susceptible 
cells) [37]. The same protein was re-discovered in 1985 
by Muchmore and Decker who isolated it from urine of 
pregnant women and described as a glycoprotein of im-
munosuppressive activity [24]. Thereafter, in 1987, Pen-
nica [26] and Hession [15] studied the structure of THP 
and UMOD and revealed that they are in the same pro-
tein. Thus, the terms “uromodulin” and “Tamm-Horsfall 
protein” may be used interchangeably; however, we have 
chosen to use the term uromodulin (UMOD) in our paper. 
Despite the fact, that uromodulin has been discovered 
in the mid-20th century, the protein is still an object of 
interest of many researchers and its numerous physiolo-
gical functions still remain rather elusive. UMOD was de-
monstrated to exhibit a tendency to gelation/aggregation 
in normal urine, that provides the water barrier on the 
luminal plasma membrane of AHL/DCT that serves as a 
physical barrier controlling water permeability and trans-
cellular ionic transport. UMOD was also revealed to be a 
“scavenger” receptor for many ligands, including numero-
us cytokines, thus it may play a modulatory role in signal 
transduction in kidneys and the urinary tract (especially 
during an inflammatory process) [33,40]. 
One of the most important physiological UMOD feature 
seems to be an ability of binding to uropathogenic strains 
of Escherichia coli. That suggests the role of UMOD in the 
defense against urinary tract infections. During coloniza-
tion of the urinary system, bacteria bind their lectin-like 
adhesin-containing fimbriae to carbohydrate structures 
and glycolipids (e.g. uroplakin Ia and Ib) present at the 
luminal urothelial cell surfaces, that act as cell receptors 
for fimbriated E coli. Binding to bacterial adhesins UMOD 
competes with uroplakins, therefore offering a protective 
effect decreasing uropathogenity of E coli [33,40].
Abnormalities in UMOD secretion (an excessive or reduced 
UMOD urine output) is observed in many renal conditions, 
such as acute renal failure [18], chronic nephropathies 
[27,31,39], interstitial cystitis [1,4], lithiasis [13,19,35,41], 
kidney transplantation [16,22,38], urinary tract infections 
[20,28,29] and others. UMOD is produced in kidneys only 
(however, there are also reports suggesting a possible 
extrarenal UMOD production, e.g. in salivary glands, je-
Fig. 4. 24-hour uromodulin  excretion in CP-HC rats
Fig. 3. 24-hour uromodulin  excretion in PBOO rats
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junum and glial cells of human brain, but UMOD mRNA 
has not been found in these tissues so far) [17]. 
Little is known about UMOD release in other stress con-
ditions, such as BPH, associated with partial urethral 
obstruction or cyclophosphamide treatment, related to 
chemical bladder damage. Therefore we have quantified 
UMOD in urine samples obtained from rats with experi-
mental models of BPH (PBOO model) and cyclophospha-
mide-induced bladder cystitis (CP-HC one). As it was men-
tioned above, in PBOO animals we have found a decline in 
urinary UMOD amount in the early phase after PBOO sur-
gery. After two weeks, UMOD excretion was even elevated 
compared to the control. A reduced urinary UMOD excre-
tion is considered to be a marker of distal tubular cells 
damage [33]. Thus, consistently, our findings suggest that 
PBOO induction and consequential intrabladder hydro-
static pressure rise, may cause subsequent DCTs damage. 
That effect is transitory: along with the structural bladder 
wall reconstruction in attempt to overcome the urinary 
outflow blockade, pressure conditions become improved 
allowing normalization of DCTs’ activity. The increased 
UMOD level two weeks after PBOO surgery may be treated 
as a compensatory, temporary effect and longer period 
of observation would be necessary to determine if the in-
creased UMOD excretion trend was stable. Our findings 
support the study reported by Storch et al. [36] who used 
different experimental model of the urine outflow blocka-
de but with similar pathophysiological consequences for 
AHL and DCT cells. The authors revealed reduced UMOD 
level in both bilateral and unilateral ureteral obstruction 
in rats, as soon as 24 hours after the surgery. Upon release 
of the blockade, UMOD urinary level returned slowly to 
normal [36]. Thus, both our and Storch et al. results sup-
port the hypothesis that urinary tract obstruction leads to 
the retrograde pressure overloading and result in UMOD 
decrease. However, there is also the study by Fasth et al. 
[12], who demonstrated that unilateral ureteral obstruc-
tion for 24 hour in mice led to the increased formation of 
UMOD at the base of DCT cells, which was also detected in 
renal interstitium for as long as 3 weeks after the release 
of the obstruction [12].
Similarly, there are also controversies concerning the 
UMOD secretion following oxazaphosphorine, alkylating 
cytotoxic agents (cyclophosphamide, ifosfamide) admi-
nistration. We have found, that CP in the experimental 
CP-HC model caused the essential total increase of UMOD 
secretion, particularly following subsequent CP doses. In 
our opinion, the elevated urinary UMOD level may be as-
sociated with a complex inflammatory response due to 
the cytotoxic CP action, particularly affecting the bladder 
in course of CP elimination. UMOD is reported to exert an 
anti-inflammatory effect binding to renal cytokines and 
lymphokines (interleukin 1, tumor necrosis factor α), the-
reby inhibiting inflammation during a kidney injury [15]. 
Taking those findings into consideration, our results would 
support the thesis that generalized inflammatory burst 
evoked by CP in urinary bladder affects also at least DCT/
AHL cells contributing to UMOD over-release, in order to 
counteract proinflammatory mediators. On the other hand, 
however, there are also reports suggesting a pro-inflam-
matory role of UMOD. That protein was demonstrated to 
activate myeloid dendritic cells and macrophages in vitro 
via the Toll-like receptor 4 [30]. Those two contradictory 
UMOD properties may be reconciled if, two different UMOD 
forms – apically- and basolaterally-released are suppose-
dly present, as suggested by El-Achkar and Wu [11]. The 
first of them may be responsible for the anti-inflammato-
ry effect, reducing activity epithelial cells and serving as a 
signal for tissue repair processes. The second one may be 
characterized by an altered, different from the apical, form 
of glycosylation, that limits the interaction of the protein 
with specific receptors present on epithelial cells and me-
diating the anti-inflammatory effects. In our study, we were 
unable to differentiate individual UMOD forms, therefore 
it is impossible to determine clearly any pro- or anti-in-
flammatory role of the elevated UMOD level observed in 
the experimental CP-HC model. We have found no other 
experimental study related to UMOD estimation in expe-
rimental CP-HC cystitis, and therefore our results cannot 
be juxtaposed with any others. There is one corresponding 
study by MacLean et al. [21] who also assessed changes in 
urine protein excretion in patients suffering from chronic 
nephrotoxicity due to oxazaphosphorine agent treatment. 
However, we cannot refer to their findings because of ma-
jor differences – comparison of results of experimental 
and clinical studies is impossible. Moreover, MacLean et al. 
[21] studied the effect of I.V. -administered ifosfamamide 
(not I.P. cyclophophosphamide) on complex protein excre-
tion, assessed using the method of gel electrophoresis. 
They demonstrated that ifosfamide treatment resulted in 
the loss of the – so called – electrophoretic band A, which 
appears to be a normal urine constituent with molecular 
weight very close to that of UMOD. They concluded that 
extensive ifosfamide-induced tubular damage might lead 
to reduced UMOD excretion. Their finding would support 
the hypothesis that decreased urinary UMOD excretion is 
considered to be a marker of distal tubular cell damage. 
However, as we mentioned above, despite the fact that our 
results are conflicting, we cannot discuss the differences 
with MacLean et al [21] study due to too gross methodo-
logical differences.
To sum up, we have revealed an overall highly increased 
urinary UMOD level in the CP-HC experimental model 
and – depending on the total/detailed point of estima-
tion – unchanged or only slightly elevated UMOD excre-
tion in 24-hour urine collections in experimental PBOO. 
The pathophysiological interpretation of those findings 
seems to be difficult due to ambiguous UMOD properties. 
It seems that qualitative and quantitative UMOD excre-
tion analysis in BPH and cystitis, as well as in other renal 
and urological abnormalities requires further studies 
to determine UMOD changes in various pathophysio-
logical conditions. Moreover, it is possible that UMOD 
assessment in numerous renal and urological disorders 
could become one of the medical analytic tools used in 
diagnostic procedures to predict future clinical course 
of particular abnormalities.
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